Time course of Graves' orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer

The risk of cancer is relatively higher in Graves' patients presenting simultaneously with thyroid nodules. Radioiodine (RAI) therapy recommended in high-risk differentiated thyroid carcinoma may be associated with worsening of a pre-existing Graves' orbitopathy (GO) or developing a new on...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2016-11, Vol.95 (48), p.e5474-e5474
Main Authors: Louvet, Camille, De Bellis, Annamaria, Pereira, Bruno, Bournaud, Claire, Kelly, Antony, Maqdasy, Salwan, Roche, Beatrice, Desbiez, Francoise, Borson-Chazot, Francoise, Tauveron, Igor, Batisse-Lignier, Marie
Format: Article
Language:English
Subjects:
Adult
Disease Progression
Female
France
Graves Ophthalmopathy - complications
Humans
Iodine Radioisotopes - therapeutic use
Male
Middle Aged
Observational Study
Retrospective Studies
Risk Factors
Thyroid Neoplasms - radiotherapy
Thyroid Neoplasms - surgery
Thyroidectomy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The risk of cancer is relatively higher in Graves' patients presenting simultaneously with thyroid nodules. Radioiodine (RAI) therapy recommended in high-risk differentiated thyroid carcinoma may be associated with worsening of a pre-existing Graves' orbitopathy (GO) or developing a new onset. The impact of RAI therapy in patients with differentiated thyroid cancer on the course of a pre-exisiting GO has not been specifically investigated.The aim of this study is to assess the influence of RAI treatment administered for differentiated thyroid cancer on the course of a pre-existing GO.This is a retrospective multicenter study including 35 patients from the University Hospital of Clermont-Ferrand (7 patients) and Lyon-Est (6 patients) in France and from a literature review published as case reports or studies (22 patients).Seven patients exhibited a worsened pre-existing GO after total thyroidectomy followed by RAI treatment for thyroid cancer. Older men, those who initially presented with a lower clinical score of GO before RAI therapy, received higher doses of I especially when prepared with recombinant thyroid-stimulating hormone, and/or not prepared with glucocorticoids during RAI are at a higher risk to worsen their GO.This study is the first and complete study collection. We describe worsening of GO in 20% of patients after RAI treatment for thyroid cancer and determine a pool of predictive factors.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000005474